Ventus Therapeutics

This structural biology-based drug discovery company was initially founded by Harvard University Academician Hao Wu. We were angel investors, investing in and incubating the project. It subsequently merged with Ventus in 2019 and secured $60 million in Series A funding from Versant Ventures and Google Ventures (GV). In 2021, it completed a $100 million Series B funding round, and in 2022, it completed a $140 million Series C funding round. Investors included SoftBank Vision Fund 2, RA Capital...

Lyndra Thetuputics

A company developing oral, ultra-long-acting, and sustained-release drug delivery technologies, with technology originating from Professor Robert Langer of MIT.

NewStem Biotechnologies Inc

The company has developed a human pluripotent cell line for autologous and allogeneic regenerative medicine and cell therapy by using advanced somatic cell nuclear transfer to obtain embryonic stem cells (SCNT-ESCs). The technology originates from Harvard University.

EarlyDiagnostics

The company focuses on providing accurate, economical, and non-invasive liquid biopsy testing services, and offering bioinformatics solutions related to cancer detection, treatment selection, and efficacy monitoring for diagnostic companies, thus contributing to early cancer detection and precision medicine.